Document Detail

Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction.
MedLine Citation:
PMID:  18483106     Owner:  NLM     Status:  MEDLINE    
Many studies have shown that a one-time 123I-metaiodobenzylguanidine (123I-MIBG) scintigraphic study during a stable period is useful for determining the prognosis of patients with chronic heart failure (CHF). However, the findings from this imaging modality are well known to be improved by medical treatment for heart failure. Accordingly, this study was performed to determine whether serial 123I-MIBG scintigraphic studies represent a reliable prognostic marker for patients with CHF. METHODS: A total of 208 patients with CHF (left ventricular ejection fraction [LVEF] < 45%) and with no cardiac events for at least 5 mo were identified on the basis of a history of decompensated acute heart failure requiring hospitalization. The delayed percentage of denervation (% denervation), delayed heart-to-mediastinum count (H/M) ratio, and washout rate (WR) were determined from the patients' 123I-MIBG images just before they left the hospital and after they had received 6 mo of treatment. The left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and LVEF were also determined by echocardiography at the same time points. RESULTS: Of the 208 patients, 56 experienced fatal cardiac events during the study. The mean follow-up period was 4.45 +/- 1.82 y. The baseline H/M ratio and WR; follow-up % denervation, H/M ratio, and WR; Delta-% denervation, H/M ratio, and WR; baseline LVEF; follow-up LVEDV, LVESV, and LVEF; and Delta-LVEDV, Delta-LVESV, and Delta-LVEF were significantly worse in the cardiac death group. A Cox regression analysis showed that the Delta-WR was an independent predictor of cardiac death. Moreover, sudden death occurred in 13 of the 56 patients with cardiac death. A Cox regression analysis also showed that the Delta-WR was an incremental predictor of sudden death. The cardiac death-free rate and sudden death-free rate were significantly higher in patients with Delta-WR less than -5% and Delta-WR less than -2% than in patients with Delta-WR greater than or equal to -5% and Delta-WR greater than or equal to -2%. CONCLUSION: Delta-WR obtained from serial 123I-MIBG scintigraphic studies can be useful for predicting cardiac death and sudden death in stabilized patients with CHF.
Shu Kasama; Takuji Toyama; Hiroyuki Sumino; Minato Nakazawa; Naoya Matsumoto; Yuichi Sato; Hisao Kumakura; Yoshiaki Takayama; Shuichi Ichikawa; Tadashi Suzuki; Masahiko Kurabayashi
Related Documents :
15986006 - Echocardiography in adults with congenital heart disease.
2998536 - Severe hypotension after first dose of enalapril in heart failure.
19201526 - The efficacy of direct extracranial-intracranial bypass in the treatment of symptomatic...
18203116 - Factors associated with non-adherence to therapy with warfarin in a population of chron...
10685856 - Cerebellar deficit and respiratory impairment: a strong association in multiple sclerosis?
20706786 - The incidence of low egfr and proteinuria in a large tertiary referral lipid clinic.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2008-05-15
Journal Detail:
Title:  Journal of nuclear medicine : official publication, Society of Nuclear Medicine     Volume:  49     ISSN:  0161-5505     ISO Abbreviation:  J. Nucl. Med.     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-05-30     Completed Date:  2008-07-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0217410     Medline TA:  J Nucl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  907-14     Citation Subset:  IM    
Department of Medicine and Biological Science (Cardiovascular Medicine), Gunma University Graduate School of Medicine, Gunma, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
3-Iodobenzylguanidine / diagnostic use*
Chronic Disease
Heart Failure / mortality*,  radionuclide imaging*
Japan / epidemiology
Radiopharmaceuticals / diagnostic use
Reproducibility of Results
Risk Assessment / methods*
Risk Factors
Sensitivity and Specificity
Stroke Volume*
Survival Analysis
Survival Rate
Ventricular Dysfunction, Left / mortality,  radionuclide imaging*
Reg. No./Substance:
0/Radiopharmaceuticals; 77679-27-7/3-Iodobenzylguanidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quantitation of CXCR4 expression in myocardial infarction using 99mTc-labeled SDF-1alpha.
Next Document:  Evaluation of the efficacy of a small CdTe gamma-camera for sentinel lymph node biopsy.